Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 406 entries
Sorted by: Best Match Show Resources per page
WITHDRAWN: Association of TNF-α-308G>A polymorphisms with hepatocellular carcinoma in Han Chinese population: A systematic review and meta-analysis.

Clinics and research in hepatology and gastroenterology

Wang F, Chen S, Xu R.
PMID: 25497275
Clin Res Hepatol Gastroenterol. 2014 Dec 08; doi: 10.1016/j.clinre.2014.10.004. Epub 2014 Dec 08.

The Editor and Publisher of "Clinics and Research in Hepatology and Gastroenterology" have decided to withdraw this article because they consider that it has been accepted based upon the positive advice of at least one faked reviewer report. This...

Cite
Wang F, Chen S, Xu R. WITHDRAWN: Association of TNF-α-308G>A polymorphisms with hepatocellular carcinoma in Han Chinese population: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2014;doi: 10.1016/j.clinre.2014.10.004.
Wang, F., Chen, S., & Xu, R. (2014). WITHDRAWN: Association of TNF-α-308G>A polymorphisms with hepatocellular carcinoma in Han Chinese population: A systematic review and meta-analysis. Clinics and research in hepatology and gastroenterology, . https://doi.org/10.1016/j.clinre.2014.10.004
Wang, Feng, et al. "WITHDRAWN: Association of TNF-α-308G>A polymorphisms with hepatocellular carcinoma in Han Chinese population: A systematic review and meta-analysis." Clinics and research in hepatology and gastroenterology vol. (2014). doi: https://doi.org/10.1016/j.clinre.2014.10.004
Wang F, Chen S, Xu R. WITHDRAWN: Association of TNF-α-308G>A polymorphisms with hepatocellular carcinoma in Han Chinese population: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2014 Dec 08; doi: 10.1016/j.clinre.2014.10.004. Epub 2014 Dec 08. PMID: 25497275.
Copy Download .nbib Format: NLM
Liver magnetic resonance diffusion weighted imaging: 2011 update.

Clinics and research in hepatology and gastroenterology

Chiaradia M, Baranes L, Pigneur F, Djabbari M, Zegai B, Brugières P, Zerbib P, Decaens T, Deux JF, Kobeiter H, Rahmouni A, Luciani A.
PMID: 21700529
Clin Res Hepatol Gastroenterol. 2011 Sep;35(8):539-48. doi: 10.1016/j.clinre.2011.05.001. Epub 2011 Jun 22.

Diffusion-Weighted-Imaging (DWI) assesses proton motion on a cellular scale. Owing to recent instrumentation developments, diffusion sequences are now routinely used for liver imaging. This review will go through the physical principles that underlie this technique, and then highlight up-to-date...

Cite
Chiaradia M, Baranes L, Pigneur F, et al. Liver magnetic resonance diffusion weighted imaging: 2011 update. Clin Res Hepatol Gastroenterol. 2011;35(8):539-48doi: 10.1016/j.clinre.2011.05.001.
Chiaradia, M., Baranes, L., Pigneur, F., Djabbari, M., Zegai, B., Brugières, P., Zerbib, P., Decaens, T., Deux, J. F., Kobeiter, H., Rahmouni, A., & Luciani, A. (2011). Liver magnetic resonance diffusion weighted imaging: 2011 update. Clinics and research in hepatology and gastroenterology, 35(8), 539-48. https://doi.org/10.1016/j.clinre.2011.05.001
Chiaradia, Mélanie, et al. "Liver magnetic resonance diffusion weighted imaging: 2011 update." Clinics and research in hepatology and gastroenterology vol. 35,8 (2011): 539-48. doi: https://doi.org/10.1016/j.clinre.2011.05.001
Chiaradia M, Baranes L, Pigneur F, Djabbari M, Zegai B, Brugières P, Zerbib P, Decaens T, Deux JF, Kobeiter H, Rahmouni A, Luciani A. Liver magnetic resonance diffusion weighted imaging: 2011 update. Clin Res Hepatol Gastroenterol. 2011 Sep;35(8):539-48. doi: 10.1016/j.clinre.2011.05.001. Epub 2011 Jun 22. PMID: 21700529.
Copy Download .nbib Format: NLM
Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: good, but can do better.

Clinics and research in hepatology and gastroenterology

Erlinger S.
PMID: 23474193
Clin Res Hepatol Gastroenterol. 2013 Apr;37(2):117-8. doi: 10.1016/j.clinre.2012.12.006. Epub 2013 Mar 06.

No abstract available.

Cite
Erlinger S. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: good, but can do better. Clin Res Hepatol Gastroenterol. 2013;37(2):117-8doi: 10.1016/j.clinre.2012.12.006.
Erlinger, S. (2013). Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: good, but can do better. Clinics and research in hepatology and gastroenterology, 37(2), 117-8. https://doi.org/10.1016/j.clinre.2012.12.006
Erlinger, Serge. "Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: good, but can do better." Clinics and research in hepatology and gastroenterology vol. 37,2 (2013): 117-8. doi: https://doi.org/10.1016/j.clinre.2012.12.006
Erlinger S. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: good, but can do better. Clin Res Hepatol Gastroenterol. 2013 Apr;37(2):117-8. doi: 10.1016/j.clinre.2012.12.006. Epub 2013 Mar 06. PMID: 23474193.
Copy Download .nbib Format: NLM
Commentary: "Cirrhosis or not cirrhosis": should we discontinue the term?.

Clinics and research in hepatology and gastroenterology

Sempoux C, Rahier J.
PMID: 22770969
Clin Res Hepatol Gastroenterol. 2012 Oct;36(5):405-7. doi: 10.1016/j.clinre.2012.05.017. Epub 2012 Jul 06.

Clinicians and pathologists are moving beyond the term cirrhosis, refining the description of this entity in parallel with a better understanding of its complexity. The objective is to accurately reflect patients' prognosis and consequently determine individual treatment and follow-up...

Cite
Sempoux C, Rahier J. Commentary: "Cirrhosis or not cirrhosis": should we discontinue the term?. Clin Res Hepatol Gastroenterol. 2012;36(5):405-7doi: 10.1016/j.clinre.2012.05.017.
Sempoux, C., & Rahier, J. (2012). Commentary: "Cirrhosis or not cirrhosis": should we discontinue the term?. Clinics and research in hepatology and gastroenterology, 36(5), 405-7. https://doi.org/10.1016/j.clinre.2012.05.017
Sempoux, Christine, and Rahier, Jacques. "Commentary: "Cirrhosis or not cirrhosis": should we discontinue the term?." Clinics and research in hepatology and gastroenterology vol. 36,5 (2012): 405-7. doi: https://doi.org/10.1016/j.clinre.2012.05.017
Sempoux C, Rahier J. Commentary: "Cirrhosis or not cirrhosis": should we discontinue the term?. Clin Res Hepatol Gastroenterol. 2012 Oct;36(5):405-7. doi: 10.1016/j.clinre.2012.05.017. Epub 2012 Jul 06. PMID: 22770969.
Copy Download .nbib Format: NLM
Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.

Clinics and research in hepatology and gastroenterology

Chen C, Qiu H, Yao Y, Zhang Z, Ma C, Ma Y, Zhao C, Xiang H, Zhao H, Zheng C, Xiong B, Li H, Long Q, Zhou J, Luo C, Hu H.
PMID: 32593695
Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101460. doi: 10.1016/j.clinre.2020.05.008. Epub 2020 Jun 24.

BACKGROUND: Transarterial chemoembolization (TACE) is widely applied in hepatocellular carcinoma (HCC) patients who are not suitable for surgical treatment. We aimed to investigate the treatment outcomes and comprehensive prognostic factors of CalliSpheres® microspheres (CSM) drug-eluting bead TACE (DEB-TACE) treatment...

Cite
Chen C, Qiu H, Yao Y, et al. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients. Clin Res Hepatol Gastroenterol. 2020;45(2):101460doi: 10.1016/j.clinre.2020.05.008.
Chen, C., Qiu, H., Yao, Y., Zhang, Z., Ma, C., Ma, Y., Zhao, C., Xiang, H., Zhao, H., Zheng, C., Xiong, B., Li, H., Long, Q., Zhou, J., Luo, C., & Hu, H. (2021). Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients. Clinics and research in hepatology and gastroenterology, 45(2), 101460. https://doi.org/10.1016/j.clinre.2020.05.008
Chen, Changyong, et al. "Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients." Clinics and research in hepatology and gastroenterology vol. 45,2 (2021): 101460. doi: https://doi.org/10.1016/j.clinre.2020.05.008
Chen C, Qiu H, Yao Y, Zhang Z, Ma C, Ma Y, Zhao C, Xiang H, Zhao H, Zheng C, Xiong B, Li H, Long Q, Zhou J, Luo C, Hu H. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients. Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101460. doi: 10.1016/j.clinre.2020.05.008. Epub 2020 Jun 24. PMID: 32593695.
Copy Download .nbib Format: NLM
Association between use of proton pump inhibitors and colorectal cancer: A nationwide population-based study.

Clinics and research in hepatology and gastroenterology

Lei WY, Wang JH, Yi CH, Liu TT, Hung JS, Wong MW, Bair MJ, Vaezi MF, Orr WC, Chen CL.
PMID: 32224118
Clin Res Hepatol Gastroenterol. 2021 Jan;45(1):101397. doi: 10.1016/j.clinre.2020.02.017. Epub 2020 Mar 27.

BACKGROUND: Proton pump inhibitors (PPIs) use is associated with hypergastrinemia and gut microbiota alteration. Concern over the risk that these factors may increase chances of colorectal cancer (CRC) has risen. To investigate the association between PPIs use and CRC...

Cite
Lei WY, Wang JH, Yi CH, et al. Association between use of proton pump inhibitors and colorectal cancer: A nationwide population-based study. Clin Res Hepatol Gastroenterol. 2020;45(1):101397doi: 10.1016/j.clinre.2020.02.017.
Lei, W. Y., Wang, J. H., Yi, C. H., Liu, T. T., Hung, J. S., Wong, M. W., Bair, M. J., Vaezi, M. F., Orr, W. C., & Chen, C. L. (2021). Association between use of proton pump inhibitors and colorectal cancer: A nationwide population-based study. Clinics and research in hepatology and gastroenterology, 45(1), 101397. https://doi.org/10.1016/j.clinre.2020.02.017
Lei, Wei-Yi, et al. "Association between use of proton pump inhibitors and colorectal cancer: A nationwide population-based study." Clinics and research in hepatology and gastroenterology vol. 45,1 (2021): 101397. doi: https://doi.org/10.1016/j.clinre.2020.02.017
Lei WY, Wang JH, Yi CH, Liu TT, Hung JS, Wong MW, Bair MJ, Vaezi MF, Orr WC, Chen CL. Association between use of proton pump inhibitors and colorectal cancer: A nationwide population-based study. Clin Res Hepatol Gastroenterol. 2021 Jan;45(1):101397. doi: 10.1016/j.clinre.2020.02.017. Epub 2020 Mar 27. PMID: 32224118.
Copy Download .nbib Format: NLM
Epidemiology of hepatitis C virus infection.

Clinics and research in hepatology and gastroenterology

Roudot-Thoraval F.
PMID: 33610022
Clin Res Hepatol Gastroenterol. 2021 May;45(3):101596. doi: 10.1016/j.clinre.2020.101596. Epub 2021 Feb 17.

Hepatitis C is a global health problem, with an estimated 71·1 million individuals chronically infected worldwide, accounting for 1% (95% uncertainty interval: 0.8-1.1) of the population. HCV transmission is most commonly associated with direct exposure to blood, via blood...

Cite
Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2021;45(3):101596doi: 10.1016/j.clinre.2020.101596.
Roudot-Thoraval, F. (2021). Epidemiology of hepatitis C virus infection. Clinics and research in hepatology and gastroenterology, 45(3), 101596. https://doi.org/10.1016/j.clinre.2020.101596
Roudot-Thoraval, Françoise. "Epidemiology of hepatitis C virus infection." Clinics and research in hepatology and gastroenterology vol. 45,3 (2021): 101596. doi: https://doi.org/10.1016/j.clinre.2020.101596
Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2021 May;45(3):101596. doi: 10.1016/j.clinre.2020.101596. Epub 2021 Feb 17. PMID: 33610022.
Copy Download .nbib Format: NLM
Endoscopic resection versus esophagectomy for patients with small-sized T1N0 esophageal cancer: A propensity-matched study.

Clinics and research in hepatology and gastroenterology

Wang W, Chen D, Sang Y, Chen C, Zhang Y, Mao Y, Chen Y.
PMID: 33554864
Clin Res Hepatol Gastroenterol. 2021 May;45(3):101543. doi: 10.1016/j.clinre.2020.09.004. Epub 2020 Oct 22.

OBJECTIVES: Endoscopic resection (ER) has been rapidly adopted in the treatment of early-stage esophageal cancer. We aimed to compare the outcomes of ER with esophagectomy for patients with small-sized (≤2 cm) stage T1a and T1b esophageal cancer in a...

Cite
Wang W, Chen D, Sang Y, et al. Endoscopic resection versus esophagectomy for patients with small-sized T1N0 esophageal cancer: A propensity-matched study. Clin Res Hepatol Gastroenterol. 2020;45(3):101543doi: 10.1016/j.clinre.2020.09.004.
Wang, W., Chen, D., Sang, Y., Chen, C., Zhang, Y., Mao, Y., & Chen, Y. (2021). Endoscopic resection versus esophagectomy for patients with small-sized T1N0 esophageal cancer: A propensity-matched study. Clinics and research in hepatology and gastroenterology, 45(3), 101543. https://doi.org/10.1016/j.clinre.2020.09.004
Wang, Wenjia, et al. "Endoscopic resection versus esophagectomy for patients with small-sized T1N0 esophageal cancer: A propensity-matched study." Clinics and research in hepatology and gastroenterology vol. 45,3 (2021): 101543. doi: https://doi.org/10.1016/j.clinre.2020.09.004
Wang W, Chen D, Sang Y, Chen C, Zhang Y, Mao Y, Chen Y. Endoscopic resection versus esophagectomy for patients with small-sized T1N0 esophageal cancer: A propensity-matched study. Clin Res Hepatol Gastroenterol. 2021 May;45(3):101543. doi: 10.1016/j.clinre.2020.09.004. Epub 2020 Oct 22. PMID: 33554864.
Copy Download .nbib Format: NLM
Peroxisome-Related Genes in Hepatocellular Carcinoma Correlated with Tumor Metabolism and Overall Survival.

Clinics and research in hepatology and gastroenterology

Liu T, Yuan Z, Wang H, Wang J, Xue L.
PMID: 34798303
Clin Res Hepatol Gastroenterol. 2021 Nov 16;101835. doi: 10.1016/j.clinre.2021.101835. Epub 2021 Nov 16.

BACKGROUND AND AIM: A prominent hallmark of tumors is aberrant lipid metabolism, and various peroxisome-related genes (PRGs) are associated with aberrant tumoral metabolic signaling. However, the influence of PRGs on the prognosis of hepatocellular carcinoma (HCC) patients remains debatable....

Cite
Liu T, Yuan Z, Wang H, et al. Peroxisome-Related Genes in Hepatocellular Carcinoma Correlated with Tumor Metabolism and Overall Survival. Clin Res Hepatol Gastroenterol. 2021;101835doi: 10.1016/j.clinre.2021.101835.
Liu, T., Yuan, Z., Wang, H., Wang, J., & Xue, L. (2021). Peroxisome-Related Genes in Hepatocellular Carcinoma Correlated with Tumor Metabolism and Overall Survival. Clinics and research in hepatology and gastroenterology, 101835. https://doi.org/10.1016/j.clinre.2021.101835
Liu, Tong, et al. "Peroxisome-Related Genes in Hepatocellular Carcinoma Correlated with Tumor Metabolism and Overall Survival." Clinics and research in hepatology and gastroenterology vol. (2021): 101835. doi: https://doi.org/10.1016/j.clinre.2021.101835
Liu T, Yuan Z, Wang H, Wang J, Xue L. Peroxisome-Related Genes in Hepatocellular Carcinoma Correlated with Tumor Metabolism and Overall Survival. Clin Res Hepatol Gastroenterol. 2021 Nov 16;101835. doi: 10.1016/j.clinre.2021.101835. Epub 2021 Nov 16. PMID: 34798303.
Copy Download .nbib Format: NLM
A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma.

Clinics and research in hepatology and gastroenterology

Yang D, Wu H, Nong W, Zheng M, Li A, Wang Y, Li M, Chen Q, Yuan S, Yu J, Liao W.
PMID: 33744828
Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101509. doi: 10.1016/j.clinre.2020.07.014. Epub 2021 Mar 19.

BACKGROUND: This study intends to explore the potential clinical value of gamma-glutamyl transpeptidase to platelet ratio (GPR) and the new multi-factor scoring model for recurrence and prognosis prediction in solitary HCC patients who received radical resection.METHODS: This study retrospectively...

Cite
Yang D, Wu H, Nong W, et al. A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2021;45(5):101509doi: 10.1016/j.clinre.2020.07.014.
Yang, D., Wu, H., Nong, W., Zheng, M., Li, A., Wang, Y., Li, M., Chen, Q., Yuan, S., Yu, J., & Liao, W. (2021). A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma. Clinics and research in hepatology and gastroenterology, 45(5), 101509. https://doi.org/10.1016/j.clinre.2020.07.014
Yang, Dongye, et al. "A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma." Clinics and research in hepatology and gastroenterology vol. 45,5 (2021): 101509. doi: https://doi.org/10.1016/j.clinre.2020.07.014
Yang D, Wu H, Nong W, Zheng M, Li A, Wang Y, Li M, Chen Q, Yuan S, Yu J, Liao W. A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101509. doi: 10.1016/j.clinre.2020.07.014. Epub 2021 Mar 19. PMID: 33744828.
Copy Download .nbib Format: NLM
Genetic polymorphism of fibroblast growth factor receptor 2 and trinucleotide repeat-containing 9 influence the susceptibility to HCV-induced hepatocellular carcinoma.

Clinics and research in hepatology and gastroenterology

Al-Khaykanee AM, Abdel-Rahman AA, Essa A, Gadallah AA, Ali BH, Al-Aqar AA, Badr EAE, Shehab-Eldeen S.
PMID: 33740609
Clin Res Hepatol Gastroenterol. 2021 Nov;45(6):101636. doi: 10.1016/j.clinre.2021.101636. Epub 2021 Mar 16.

BACKGROUND: Fibroblast growth factor receptor 2 (FGFR2) and trinucleotide repeat-containing 9 (TRNC9) gene polymorphisms have been associated with some cancers. We aimed to assess the association of FGFR2 rs2981582 and TRNC9 rs12443621 polymorphisms with hepatocellular cancer risk.METHODS: One hundred...

Cite
Al-Khaykanee AM, Abdel-Rahman AA, Essa A, et al. Genetic polymorphism of fibroblast growth factor receptor 2 and trinucleotide repeat-containing 9 influence the susceptibility to HCV-induced hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2021;45(6):101636doi: 10.1016/j.clinre.2021.101636.
Al-Khaykanee, A. M., Abdel-Rahman, A. A., Essa, A., Gadallah, A. A., Ali, B. H., Al-Aqar, A. A., Badr, E. A. E., & Shehab-Eldeen, S. (2021). Genetic polymorphism of fibroblast growth factor receptor 2 and trinucleotide repeat-containing 9 influence the susceptibility to HCV-induced hepatocellular carcinoma. Clinics and research in hepatology and gastroenterology, 45(6), 101636. https://doi.org/10.1016/j.clinre.2021.101636
Al-Khaykanee, Ahmed Mudher, et al. "Genetic polymorphism of fibroblast growth factor receptor 2 and trinucleotide repeat-containing 9 influence the susceptibility to HCV-induced hepatocellular carcinoma." Clinics and research in hepatology and gastroenterology vol. 45,6 (2021): 101636. doi: https://doi.org/10.1016/j.clinre.2021.101636
Al-Khaykanee AM, Abdel-Rahman AA, Essa A, Gadallah AA, Ali BH, Al-Aqar AA, Badr EAE, Shehab-Eldeen S. Genetic polymorphism of fibroblast growth factor receptor 2 and trinucleotide repeat-containing 9 influence the susceptibility to HCV-induced hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2021 Nov;45(6):101636. doi: 10.1016/j.clinre.2021.101636. Epub 2021 Mar 16. PMID: 33740609.
Copy Download .nbib Format: NLM
A survey of lifestyle habits, physician counseling, and direct-to consumer genetic testing in patients with hereditary hemochromatosis.

Clinics and research in hepatology and gastroenterology

Koop AH, Ghoz HM, Stancampiano FF, Nordelo K, Palmer WC.
PMID: 33676066
Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101658. doi: 10.1016/j.clinre.2021.101658. Epub 2021 Mar 03.

INTRODUCTION AND OBJECTIVES: The goal of this study was to assess lifestyle habits and physician counseling of patients with hereditary hemochromatosis (HH), and determine the prevalence of direct-to-consumer (DTC) genetic testing.MATERIALS AND METHODS: A 52-question survey was created to...

Cite
Koop AH, Ghoz HM, Stancampiano FF, et al. A survey of lifestyle habits, physician counseling, and direct-to consumer genetic testing in patients with hereditary hemochromatosis. Clin Res Hepatol Gastroenterol. 2021;45(2):101658doi: 10.1016/j.clinre.2021.101658.
Koop, A. H., Ghoz, H. M., Stancampiano, F. F., Nordelo, K., & Palmer, W. C. (2021). A survey of lifestyle habits, physician counseling, and direct-to consumer genetic testing in patients with hereditary hemochromatosis. Clinics and research in hepatology and gastroenterology, 45(2), 101658. https://doi.org/10.1016/j.clinre.2021.101658
Koop, Andree H, et al. "A survey of lifestyle habits, physician counseling, and direct-to consumer genetic testing in patients with hereditary hemochromatosis." Clinics and research in hepatology and gastroenterology vol. 45,2 (2021): 101658. doi: https://doi.org/10.1016/j.clinre.2021.101658
Koop AH, Ghoz HM, Stancampiano FF, Nordelo K, Palmer WC. A survey of lifestyle habits, physician counseling, and direct-to consumer genetic testing in patients with hereditary hemochromatosis. Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101658. doi: 10.1016/j.clinre.2021.101658. Epub 2021 Mar 03. PMID: 33676066.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 406 entries